Aug 7 (Reuters) - Drugmaker Auxilium Pharmaceuticals posted a much bigger-than-expected quarterly loss, hurt by falling sales of testosterone gel Testim.
Auxilium lost $36.5 million, or 73 cents per share, in the second quarter ended June 30, compared with a net profit of $42.7 million, or 86 cents per share, a year earlier.
Excluding items, the loss was 44 cents per share.
Analysts on average had expected the company to post a loss of 21 cents a share, according to Thomson Reuters I/B/E/S.
Total revenue fell 17.4 percent to $83 million. (Reporting by Anjali Rao Koppala in Bangalore; Editing by Saumyadeb Chakrabarty)